FR2583984B1 - Formulation pharmaceutique lyophilisee d'activateur tissulaire du plasminogene, procede pour la preparer, recipient obture la contenant et sel d'activateur tissulaire du plasminogene - Google Patents

Formulation pharmaceutique lyophilisee d'activateur tissulaire du plasminogene, procede pour la preparer, recipient obture la contenant et sel d'activateur tissulaire du plasminogene

Info

Publication number
FR2583984B1
FR2583984B1 FR8607552A FR8607552A FR2583984B1 FR 2583984 B1 FR2583984 B1 FR 2583984B1 FR 8607552 A FR8607552 A FR 8607552A FR 8607552 A FR8607552 A FR 8607552A FR 2583984 B1 FR2583984 B1 FR 2583984B1
Authority
FR
France
Prior art keywords
tissue activator
plasminogen tissue
same
salt
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8607552A
Other languages
English (en)
French (fr)
Other versions
FR2583984A1 (fr
Inventor
Michael Denis Johnston
Henry Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of FR2583984A1 publication Critical patent/FR2583984A1/fr
Application granted granted Critical
Publication of FR2583984B1 publication Critical patent/FR2583984B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR8607552A 1985-05-28 1986-05-27 Formulation pharmaceutique lyophilisee d'activateur tissulaire du plasminogene, procede pour la preparer, recipient obture la contenant et sel d'activateur tissulaire du plasminogene Expired FR2583984B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (2)

Publication Number Publication Date
FR2583984A1 FR2583984A1 (fr) 1987-01-02
FR2583984B1 true FR2583984B1 (fr) 1989-06-02

Family

ID=26289290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8607552A Expired FR2583984B1 (fr) 1985-05-28 1986-05-27 Formulation pharmaceutique lyophilisee d'activateur tissulaire du plasminogene, procede pour la preparer, recipient obture la contenant et sel d'activateur tissulaire du plasminogene

Country Status (22)

Country Link
US (2) US4929444A (enExample)
JP (1) JPH0759517B2 (enExample)
AU (1) AU567236B2 (enExample)
BE (1) BE904830A (enExample)
CA (1) CA1300008C (enExample)
CH (1) CH665356A5 (enExample)
DE (1) DE3617752A1 (enExample)
DK (1) DK163173C (enExample)
ES (2) ES8800601A1 (enExample)
FI (1) FI85335C (enExample)
FR (1) FR2583984B1 (enExample)
GB (1) GB2176702B (enExample)
GR (1) GR861366B (enExample)
HU (1) HU195733B (enExample)
IL (1) IL78938A (enExample)
IT (1) IT1191926B (enExample)
LU (1) LU86444A1 (enExample)
NL (1) NL8601355A (enExample)
NO (1) NO171345C (enExample)
NZ (1) NZ216307A (enExample)
PT (1) PT82646B (enExample)
SE (1) SE462016B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO171344C (no) * 1985-05-28 1993-03-03 Wellcome Found Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
JPH0680015B2 (ja) * 1986-05-12 1994-10-12 ザ ウエルカム ファウンデーション リミテッド 医薬組成物
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (en) * 1991-01-14 1992-07-23 Duke University LAMININ SEQUENCE AS tPA ACTIVATOR
DE69333127T2 (de) * 1992-06-03 2004-05-06 Genentech, Inc., South San Francisco Varianten des Gewebeplasminogenaktivators mit verbesserter therapeutischer Wirkung
JP3840262B2 (ja) * 1995-10-23 2006-11-01 ザ チルドレンズ メディカル センター コーポレイション 治療用の抗血管新生組成物および方法
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
KR100477280B1 (ko) * 1995-12-13 2005-07-18 아보트 러보러터리즈 맥관형성에의한질환치료제
DE69719265T2 (de) * 1996-09-06 2003-12-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
EP1636337A4 (en) * 2003-06-20 2007-07-04 Illumina Inc METHODS AND COMPOSITIONS USEFUL FOR THE AMPLIFICATION AND GENOTYPING OF THE GENOME
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US8822535B2 (en) * 2005-04-20 2014-09-02 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (enExample) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
EP0124613B1 (en) * 1982-10-29 1992-12-30 MITSUI TOATSU CHEMICALS, Inc. Novel plasminogen activator derived from human kidneys, process for its preparation, and thrombolytic drug containing the same
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
AU567236B2 (en) 1987-11-12
PT82646B (pt) 1989-01-30
GB2176702B (en) 1989-07-05
SE8602405D0 (sv) 1986-05-27
GB2176702A (en) 1987-01-07
FR2583984A1 (fr) 1987-01-02
AU5796486A (en) 1986-12-04
IT1191926B (it) 1988-03-31
SE462016B (sv) 1990-04-30
LU86444A1 (fr) 1986-12-05
IL78938A0 (en) 1986-09-30
IL78938A (en) 1993-02-21
DE3617752A1 (de) 1986-12-04
DK163173C (da) 1992-06-22
FI862227L (fi) 1986-11-29
IT8648065A0 (it) 1986-05-27
ES8800601A1 (es) 1987-11-16
NO171345C (no) 1993-03-03
NO171345B (no) 1992-11-23
US4929444A (en) 1990-05-29
HU195733B (en) 1988-07-28
CA1300008C (en) 1992-05-05
US4968617A (en) 1990-11-06
GR861366B (en) 1986-09-29
NO862096L (no) 1986-12-01
BE904830A (fr) 1986-11-27
PT82646A (en) 1986-06-01
FI862227A0 (fi) 1986-05-27
DK246786A (da) 1986-11-29
GB8612780D0 (en) 1986-07-02
ES555353A0 (es) 1987-11-16
NL8601355A (nl) 1986-12-16
CH665356A5 (de) 1988-05-13
DK163173B (da) 1992-02-03
ES557374A0 (es) 1988-06-01
JPH06183995A (ja) 1994-07-05
DK246786D0 (da) 1986-05-27
NZ216307A (en) 1989-10-27
FI85335C (fi) 1992-04-10
HUT41638A (en) 1987-05-28
JPH0759517B2 (ja) 1995-06-28
DE3617752C2 (enExample) 1988-06-30
SE8602405L (sv) 1986-11-29
FI85335B (fi) 1991-12-31
ES8802439A1 (es) 1988-06-01

Similar Documents

Publication Publication Date Title
FR2593393B1 (fr) Solution aqueuse a usage parenteral d'activateur tissulaire du plasminogene, procede pour la preparer et recipient obture la contenant
FR2569402B1 (fr) Derives d'acide 3,5-pyridine-dicarboxylique, procede pour leur preparation et composition pharmaceutique les contenant
FR2583429B1 (fr) Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
FR2595351B1 (fr) Derives d'indole, procede pour leur preparation et compositions pharmaceutiques les contenant
HUT43808A (en) Process for production of new derivatives of n-/2'-aminphenil/-benzamid and medical preparatives containing thereof as active substance
HUT41638A (en) Process for preparing a pharmaceutical composition containing tissue plasminogen activator
FR2501204B1 (fr) Derives d'un acide quinoleine-carboxylique, procede pour les preparer et medicament en contenant
PT83896A (fr) Procede pour la preparation de nouveaux conjuges de la vinblas-tine et de ses derives et de compositions pharmaceutiques les contenant
FR2560046B1 (fr) Produit dietetique utile pour diminuer la concentration de l'uree dans les liquides physiologiques et procede pour sa preparation
FR2642065B1 (fr) Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
FR2569702B1 (fr) Nouvelle 4'-deschlororebeccamycine, composition pharmaceutique la contenant et procede pour sa preparation
FR2599034B1 (fr) Derives de 1-(hydroxystyryl)-5h-2,3,-benzodiazepine, procede pour les preparer et compositions pharmaceutiques les contenant
FR2584405B1 (fr) Sels de furosemide, composition pharmaceutique les contenant et leur procede de preparation
HUT42510A (en) Process for preparing biologically active derivatives of humane gamma-interferone and pharmaceutical compositions containing such compounds
PT79365A (fr) Procede de preparation de derives d'imidazoline et de compositions pharmaceutiques les contenant
FR2548539B1 (fr) Composition pharmaceutique contenant un lubrifiant liquide et procede pour ameliorer la dissolution de capsules en gelatine dure ou de comprimes contenant des formules therapeutiques et un lubrifiant
FR2600061B1 (fr) Derives d'indole, composition pharmaceutique les contenant et procede pour leur preparation
FR2628419B1 (fr) Nouveaux sels antiviraux, compositions pharmaceutiques les contenant et procede pour les preparer
FR2517670B1 (fr) Sel d'acide (+)-2-(2-fluoro-4-biphenylyl)propionique, procede pour sa preparation et composition pharmaceutique le contenant
FR2551359B3 (fr) Procede et appareil pour la preparation de produits contenant de l'air emprisonne
FR2446819B1 (fr) Derives 6-alkyles d'acide 1,2-dihydro-2-oxonicotinique et composition pharmaceutique les contenant
HUT46910A (en) Process for production of new /benzofurane-2-il/-imidasole derivatives and their salts and medical preparatives containing such substances
PT79712B (fr) Procede de preparation de compositions nutritives contenant de l'acide alpha-cetoisocaproique ou un de ses sels et de medicaments les contenant
PT66489B (fr) Procede pour la preparation des produits pharmaceutique contenant polihydroxiphenil cromanones
FR2605623B1 (fr) Procede de preparation de particules magnetiques d'hexaferrites, particules obtenues et produits les contenant

Legal Events

Date Code Title Description
ST Notification of lapse
ST Notification of lapse